Astellas Initiates P-III BRIGHT SKY Clinical Program for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms

 Astellas Initiates P-III BRIGHT SKY Clinical Program for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms

Shots:

  • Astellas to initiate global BRIGHT SKY program which includes three P-III studies (SKYLIGHT 1, SKYLIGHT 2 and SKYLIGHT 4) and will assess fezolinetant (30/45mg, qd) in postmenopausal women with VMS i.e, hot flashes and night sweats associated with menopause.
  • The P-III SKYLIGHT 1&2 will assess Fezolinetant vs PBO for 12wks. and will each enroll ~450 women followed by non-controlled 40wks. extension period across 200 sites. The P-III SKYLIGHT 4 study will evaluate Fezolinetant vs PBO in ~ 1,150 women with VMS to investigate long-term safety across 250 sites
  • Fezolinetant is an oral, non-hormonal therapy which acts by targeting neurokinin-3 (NK3) receptor and normalizing KNDy neuron activity further modulating the temperature control center and reducing the frequency + severity of hot flashes

Click here to­ read full press release/ article | Ref: Astellas | Image: Yahoo Finance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post